Kudos to Shannon!
"The Drug-Trial Registry" at the New York Times Magazine:
(requires free login)
Shannon provides a nice snapshot of the issues we have reviewed on the listserv.
- Problems with negative studies
- The FDA's role
- Pharma vs. independent (DTR) database
- Study phases and data availability
The exposure in NYTM in and of itself is nice to see. Very broad acceptance will be necesary in order to change the status quo (especially when pharma just hired a new top gun lobbyist).
Egan
Shannon Brownlee's article is also available at:
ReplyDeletehttp://www.newamerica.net/index.cfm?pg=article&DocID=2094
without requiring a log-in.